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Abstract
AIM: To study the expression of cyclooxygenase-2 (COX-2)
in human gastric cancer tissues and their paired adjacent
mucosa, as well as mucosa from gastric antrum and corpus
of the first-degree relatives of the recruited cancer patients.
METHODS: The expression of COX-2 mRNA in 38 patients
with gastric cancer and their 29 first-degree relatives and
18 healthy controls was assessed by the real time RT-PCR.
The expression of COX-2 protein was determined by
Western blot.
RESULTS: A marked increase in COX-2 mRNA expression
was found in 20 of 37 (54%) cancerous tissues compared
to their respective paired normal mucosa (P<0.001).
Interestingly, increased COX-2 mRNA expression was also
found in mucosa of the corpus (6/29) and antrum (13/29)
of their first-degree relatives. Increased COX-2 mRNA
expression was more frequently observed in the antrum
biopsies from cancer patients than in the antrum biopsies
from healthy controls (P<0.05). In addition, 3 of 23 (13%)
patients with atrophic mucosa and 6 of 35 (17%) patients
with intestinal metaplasia showed increased COX-2 mRNA
expression. Furthermore, COX-2 expression increased in
H pylori-positive tissues, especially in antrum mucosa.
CONCLUSION: Increased COX-2 expression is involved
in gastric carcinogenesis, and may be necessary for
maintenance of the malignant phenotype and contribute
to Helicobacter pylori-associated malignant transformation.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Gastric cancer is one of the most common malignancies in
China and the most frequent cause of cancer-related death[1].
Although its incidence is increasing, it is still the second
most commonly diagnosed fatal cancer worldwide[2].
Unfortunately, gastric tumors are usually diagnosed at
their advanced stage and the current 5-year survival rate is
only 17%. Development of gastric cancer, like many other
malignancies, is a multi-step process involving the accumulation
of genetic alterations. However, much remains to be learned
about the molecular pathogenesis of gastric cancer progression
and new molecular targets are needed for the prevention
and treatment of gastric cancer, especially in its early stage.
Previous studies showed that about 10% of gastric cancer
patients exhibit familial clustering[3,4], and a high prevalence
of intestinal metaplasia has been found to be in the first-
degree relatives of patients with gastric cancer in contrast
to age-matched controls. Thus, the first-degree relatives are
considered to be in pre-malignant state[5]. Therefore,
identification of genes predisposing to familial cancer is an
essential step towards understanding the molecular events
underlying tumorigenesis and is critical for the clinical
management of affected families.
Prostaglandins play an important role in the protection
of the upper gastrointestinal tract mucosa against injurious
agents. Prostaglandin production in the gastro-duodenal
mucosa is due to a single isoform of  cyclooxygenase (COX)[6].
Two COX isoforms, COX-1 and -2, have been identified[7].
COX-1 is a housekeeping gene that is constantly expressed
in a number of  cell types, whereas COX-2 is an early
responsive gene that is rapidly induced by growth factors,
tumor promoters, oncogenes, and carcinogens[8]. COX-2
products have also been shown to be mutagenic[9] and
tumorigenic[10]. Multiple lines of  evidence suggest that
COX-2 plays an important role in the malignant transformation
of cells[11] including various cancer cells[12]. In contrast, levels
of  COX-1 are relatively constant. Recently, the importance
of  COX-2 in gastro-intestinal carcinogenesis has been
recognized. In humans, COX-2 is frequently detected in
the majority of colon tumor samples and is involved in
early events of colon carcinogenesis[13,14]. Indeed, increased
COX-2 expression has been observed in gastric carcinoma
with no alteration in the levels of  COX-1[15]. Whether COX-2
is associated with early gastric carcinogenesis in humans,
especially in gastric mucosa of the first-degree relatives of
gastric cancer patients, remains unclear. In this study, we
aimed to detect the expression level of  COX-2 in gastric
cancer and non-cancerous tissues to look for a possible
relationship between the development of gastric cancer and
COX-2 expression.
MATERIALS AND METHODS
Subjects
Fifty patients with gastric cancer (mean age 66 years, range
50-87 years), 29 of their first-degree relatives (mean age
50 years, range 27-74 years) and 18 healthy subjects without
gastric cancer family history (mean age 58 years, range
24-86 years) were recruited in this study. Tissues were
collected from tumor area and their adjacent non-tumor
corpus and antrum of cancer patients, their first-degree
relatives and healthy subjects. Two or three biopsies were
snap-frozen in liquid nitrogen for mRNA and protein
analysis, and two additional specimens were fixed in 10%
buffered formalin for routine histology. Written informed
consent was obtained from all participants before
commencement of the study.
Histology
Formalin fixed tissues were processed and stained with
hematoxylin and eosin, for routine histological evaluation.
Helicobacter pylori (H pylori) was detected by Warthin-Starry
staining[16]. Histological classification of gastric cancer type
was based upon Lauren system which divides gastric cancer
into intestinal or diffuse type. The severity of gastritis and
H pylori colonization status of the non-tumorous gastric
mucosa were determined by updated Sydney System[17]. All
histological sections were reviewed by an experienced gastro-
intestinal pathologist.
RNA and protein isolation
Gastric tissue specimens were homogenized with an
ultrasonographic homogenizer. Total RNA and proteins were
sequentially extracted using TRIzol reagents (CINNA/MRC,
Cincinnati, OH, USA), according to the manufacturer’s instructions.
RT-PCR
One microgram of total RNA was reverse transcribed using
dNTPs (1 mol/L), 5× reverse transcription (RT) buffer
(500 mol/L Tris-HCl, pH 8.3, 250 mol/L KCl, 50 mol/L
MgCl2, and 50 mol/L DTT), 16 units RNasin, and 2.5 units
of  AMV reverse transcriptase (Gibco-BRL, Life Technologies).
mRNA expression of  COX-2 was first determined by
conventional RT-PCR. One microliter of  reverse-transcription
product (cDNA) was amplified by PCR using 1 U of
Ampli-Taq DNA polymerase (Gibco-BRL), and 6 pmoL
each of  COX-2 forward and reverse primers, with 6 pmoL
each of forward and reverse -actin primers included in
the same multiplex PCR reaction, as an internal control for
efficiency of RT and amount of RNA. Each PCR cycle
consisted of a denaturation at 94 ℃ for 28 s, an annealing
at 60 ℃ for 48 s and an elongation at 72 ℃ for 1 min. A
total of  30 cycles were performed with an additional
extension at 72 ℃ for 5 min. The primer sequences and
PCR product sizes were as follows: cox-2, sense 5’-
AGATCATCTCTGCCTGAGTATCTT-3’, anti-sense 5’-
TTCAAATGAGATTGTGGGAAAAT-3’, with a 305-bp
amplification; -actin, sense, 5’-TGACGGGGTCACCC-
ACACTGTGCCCATCTA-3’, anti-sense, 5’-CTAGAAGC-
ATTTGCGGTGGACGATGGAGGG-3’ with a 654-bp
amplification. PCR products were separated on 1.5%
agarose gels with 0.5 µg/mL of ethidium bromide, and
stained bands were visualized under UV light, photographed,
and digitized with a scanner.
Real-time quantitative PCR was then performed on ABI
PRISM 7000 sequence detection system using Sybrgreen,
PCR mastermix (Perkin Elmer, Branchburgh, NJ, USA)
and primers. Primer sequences were designed from the
GenBank as follows: COX-2, (forward) 5’- GCCCTTCC-
TCCTGTGCC-3’, (reverse) 5’-AATCAGGAAGCTGC-
TTTTTAC-3’; and -actin, (forward), 5’-CTAATGGGCA-
CCCAGCACAATG-3’, (reverse) 5’-GCCGATCCACA-
CGGAGTACT-3’. A 24-µL reaction mix was aliquot with
1 µL/replicate of cDNA. A DNA-free template control
(containing water) was included and each sample was added
in duplicate. Reaction tubes were sealed with optical caps,
and the PCR reaction was run at 50 ℃ for 2 min, at 95 ℃
for 10 min, followed by 40 cycles at 96 ℃ for 45 s, at 60 ℃
for 45 s and at 72 ℃ for 1 min. Specificity of PCR products
was characterized by melting curve analysis and followed
by gel electrophoresis. Quantification was determined by
the threshold cycle. Actin was used as a housekeeping
gene to normalize mRNA levels and compared to mRNA
expression levels in normal control stomach.
Western blotting
Total protein concentration was determined by the method
of Bradford (DC protein assay, Bio-Rad, Hercules, CA, USA).
Fifteen micrograms of protein was separated by 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then
transferred onto equilibrated polyvinylidene difluoride
membrane (Amersham Biosciences, Buckinghamshire, UK)
by electroblotting. Membranes were blocked using 5% skim
milk, and then incubated with primary antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) against COX-2
(1:1 000) or -actin (1:1 000) overnight at 4 ℃. After
incubation with secondary antibody, proteins were detected by
enhanced chemiluminescence (ECL, Amersham Corporation),
and bands were quantified by scanning densitometry using
the SCAN Control (Scanco~1.lnk) imaging system.
Statistical analysis
Statistical association between COX-2 expression and various
clinicopathological factors was determined using the 2 test.
An exact comparison densitometric analysis of  COX-2 PCR
products was performed by Student’s t-test. P<0.05 was
considered statistically significant.
RESULTS
COX-2 expression in gastric cancer
Increased COX-2 mRNA expression was detected in 37 of
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50 (74%) gastric cancer tissues, COX-2 mRNA expression
was found to be at very low levels in adjacent gastric mucosa,
with 6 of 34 (18%) corpus tissues and 2 of 35 (6%) antrum
tissues showing positive COX-2 expression (Table 1 and
Figure 1). Quantitative analysis showed that tumor tissues
expressed significantly higher levels of  COX-2 mRNA
compared to the adjacent antrum or corpus samples
(Figure 2). COX-2 mRNA was expressed in both intestinal
and diffuse types of gastric cancer and did not show any
significant difference. By Western blot, COX-2 protein
expression was found in 15 of 24 (62.5%) cancers and 4
of 24 (16.7%) adjacent non-tumor specimens (Figure 3).
There was a significant correlation between COX-2 mRNA
and COX-2 protein expression in gastric tumor samples
(r = 0.522; P = 0.001).
Figure 1  RT-PCR analysis of COX-2 mRNA in gastric tissues. Lanes 1-4:
gastric cancer; lanes 5 and 6: first-degree relatives; lanes 7 and 8: healthy
control; lane 9: negative control; lane 10: 100-bp DNA ladder. T: Tumor; NT:
adjacent non-tumor; C: corpus, and A: antrum.
Figure 2  Quantitative RT-PCR analysis of COX-2 mRNA in gastric tissues.
GC: gastric cancer; FDR: first degree relatives.
Figure 3  COX-2 protein expression in gastric tissues. T: Tumor; NT: adjacent
non-tumor; C: corpus, and A: antrum.
Expression of COX-2 in gastric mucosa of first degree relatives
We also studied the COX-2 expression in 29 first-degree
relatives of  gastric cancer patients, and in 18 normal
subjects without family history of gastric cancer. Increased
COX-2 mRNA expression was observed in 6 of  29 (20.1%)
corpus tissues and in 13 of 29 (44.8%) antrum tissues of
first-degree relatives (Figure 1). In contrast, only 1 of 18
normal controls exhibited very low COX-2 mRNA
expression in both corpus and antrum tissues. Quantitative
analysis showed that expression of  COX-2 mRNA increased
in corpus and antrum tissues of first-degree relatives
compared to healthy controls (P<0.01, Figure 2). Weakly
positive COX-2 protein was detected in the mucosa of  first
degree relatives (Figure 3), whereas it was undetectable in
normal controls.
We then proceeded to investigate the COX-2 expression
in two pre-cancerous conditions: atrophic mucosa and
mucosa with intestinal metaplasia, to determine whether
upregulation of this gene occurred at an earlier stage in
malignant transformation. COX-2 mRNA was upregulated
in 3 of 23 (13%) cases of mucosal atrophy and 6 of 35
(17%) cases of intestinal metaplasia.
Table 1  COX-2 mRNA expression in gastric tissues
               COX-2 mRNA expression
Tissues %
 +  –
Gastric cancer 20 17 54
Paired adjacent corpus   6 28 18
Paired adjacent antrum   2 33   6
Corpus of first-degree relatives   6 23 21
Antrum of first-degree relatives 13 16 45
Corpus of  healthy control   1 17   6
Antrum of healthy control   1 17   6
Correlation of COX-2 expression with H pylori infection
We compared the COX-2 mRNA expression in H pylori
infected and H pylori-negative tissues (Table 2). RT-PCR
analysis of the gastric tissues showed that the expression of
COX-2 was significantly upregulated in H pylori infected
tissues compared to H pylori-negative tissues (P<0.05).
Because H pylori is most commonly colonized in gastric
antrum[18], we also compared the levels of  COX-2 expression
in H pylori infected antrum and corpus tissues, and found
that the expression of  COX-2 mRNA was significantly
higher in the antrum (P<0.05).
Table 2  Correlation between COX-2 mRNA expression and H pylori
infection
 COX-2 mRNA expression
H pylori              Antrum   %    Corpus        %          Total          %
Positive                12/34    35      8/36         22          20/70          29
Negative                  4/44     9      4/39         10            8/83          10
P   <0.005         >0.05             <0.005
DISCUSSION
Gastric cancer is one of the most commonly encountered
malignancies worldwide. Several of its pre-cancerous
conditions, such as atrophic gastritis and intestinal metaplasia,
have been well recognized. The concern with these gastric
cancer precursor conditions or lesions is related to the
attempt to prevent carcinoma or to detect it at an early
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stage. Atrophic gastritis is defined as the loss of gastric glands,
which can occur either in antrum or in corpus. Increased
prevalence of this type of gastritis has been found in subjects
who are at high risk for gastric cancer[19]. Intestinal metaplasia
is defined as the replacement of gastric mucosa by glands
that have the characteristics of the small intestine[20], and
this condition has been strongly associated with development
of gastric cancer. Atrophic gastritis and intestinal metaplasia
have been accepted as pre-cancerous conditions for some
years. Generalized genetic instability has been shown to occur
early in this process[21,22]. In contrast, the relative contributions
of inherited susceptibility and environmental effects to
familial gastric cancer are poorly understood, because little
is known about the genetic events that predispose to gastric
cancer. The first-degree relatives of gastric cancer patients
have a three-fold risk for developing gastric carcinoma[3,9].
Therefore, the identification of genes predisposing to familial
cancer is an essential step towards understanding the
molecular events underlying tumorigenesis and critical for
the clinical management of affected families.
In our study, COX-2 gene expression was undetectable
in normal control gastric mucosa. In the majority of
gastric carcinomas studied, COX-2 expression was clearly
upregulated compared to the levels of expression in
accompanying antrum and corpus mucosa devoid of cancer
cells. A similar pattern of  COX-2 mRNA expression has
previously been found in human gastric carcinoma[23]. More
importantly in this study, upregulation of  COX-2 mRNA
and protein was found in first-degree relatives. Furthermore,
we detected COX-2 expression in atrophic mucosa and in
intestinal metaplasia. These results suggest that COX-2
overexpression constitutes an early event in the gastric
neoplastic transformation process which occurs at the
pre-cancerous stage. Similarly, expression of  COX-2 is found
in some non-malignant hyperplastic gastric glands that may
represent pre-malignant lesions stained for the COX-2
protein[23]. Expression of  COX-2 is also found in rat
epidermis during hyperplastic transformation[24]. In addition,
colonic epithelium expresses only low levels of  COX-2
mRNA and elevated levels are found in more than 40% of
pre-malignant colonic adenomas. COX-2 expression is
detected in hyperplastic bronchial epithelium and atypical
alveolar epithelium in lung specimens[25]. COX-2 is involved
in Barrett’s-associated metaplastic and dysplastic specimens[17].
All these findings strongly suggest that COX-2 may play a
role in early carcinogenesis.
H pylori has been epidemiologically linked to gastric
cancer and classified as a class I carcinogen by the World
Health Organization[26]. In the present study, expression of
COX-2 mRNA was upregulated in gastric mucosa from
H pylori-positive tissues compared to H pylori-negative tissues,
suggesting that induction of  COX-2 may be a specific
response to H pylori infection. COX-2 mRNA expression
was significantly correlated with H pylori infected antrum
tissues, but not with H pylori infected corpus tissues. A more
important factor may be the consistent finding that H pylori
infection density is greater in gastric antrum than in
corpus[27,28]. Therefore, the overexpression of  COX-2 may
be a direct effect of H pylori.
In conclusion, gastric cancer and pre-cancerous lesions
express COX-2. COX-2 mRNA is detectable in gastric
mucosa of  first-degree relatives of  cancer patients. COX-2
may contribute to H pylori associated neoplastic transformation.
Further investigation is necessary to determine the putative
role of this gene in gastric carcinogenesis.
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